Zeenews Bureau In what may be seen as a positive development, it has emerged that the anti-estrogen drug Aromasin reduces the risk of breast cancer recurrence by about one-third in postmenopausal women previously treated with tamoxifen. According to researchers, `Aromasin`, which has been approved by the FDA, obstructs the production of estrogen that is made outside of the ovaries.
Two other drugs, tamoxifen and raloxifene have also been approved by the FDA for cancer prevention though they have side effects like blood clots, strokes, leg cramps and joint pain.
No bugging at Gadkari`s home: Rajnath Singh
Massive landslide buries Pune`s Malin village
Heavy rains lash several parts of India
Delhi shame: Class 10th student gang-raped in Uttam Nagar at gun point